MANN’S PHARMACOVIGILANCE

Third edition

Edited by

ELIZABETH B. ANDREWS PhD, MPH, FISPE
Vice President, Pharmacoepidemiology and Risk Management
RTI Health Solutions
Research Triangle Park, NC, USA

NICHOLAS MOORE MD, PhD, FRCP(Edin), FISPE
Professor of Clinical Pharmacology
Service Hospitalo-Universitaire de Pharmacologie
Bordeaux, France

WILEY Blackwell
Contents

Contributors........................................................................................................................................ xi
Foreword........................................................................................................................................................ xxi

1 Introduction: Updated from Second Edition ..................................................................................... 1
Ronald D. Mann and Elizabeth B. Andrews

2 History of Pharmacovigilance .................................................................................................................. 11
Judith K. Jones and Elyse Kingery

I THE REGULATORY BASIS OF PHARMACOVIGILANCE

3 Legal Basis: European Union ................................................................................................................. 27
Brian Edwards, Calvin Johnson, and Shelley Gandhi

4 Ethical Oversight, Consent, and Confidentiality ...................................................................................... 37
Suzanne L. West and Wendy A. Visscher

5 Pharmacovigilance-Related Topics at the Level of the International Conference
  on Harmonisation ................................................................................................................................. 47
Priya Bahri

6 The Council for International Organizations of Medical Sciences Working Groups and Their
  Contributions to Pharmacovigilance ....................................................................................................... 63
Gunilla Sjölin-Forsberg and William Gregory

7 Terminologies in Pharmacovigilance .................................................................................................... 77
Elliot Brown and Daniel von Sydow

8 Nonclinical Toxicological Support for Phase I Trials ........................................................................... 95
David R. Jones and James W. McBlane

9 The Evaluation of Adverse Events in Clinical Trials (with a Particular Focus
  on the Use of Meta Analysis) .............................................................................................................. 109
Jesse A. Berlin, Brenda Crowe, and H. Amy Xia

10 Case Reports as Evidence in Pharmacovigilance ............................................................................... 121
Jeffrey K. Aronson
11 Periodic Safety Update Reports .................................................................139
   Patrice Verpillat and Mondher Toumi
12 The Principles behind Risk Management in the European Union ......................153
   Stella C.F. Blackburn and June M. Raine

II PHARMACOVIGILANCE SYSTEMS

Pharmacovigilance in Europe
13a Regulatory Pharmacovigilance in the European Union ..................................173
   Priya Bahri and Peter Arlett
13b Spontaneous Reporting: United Kingdom ....................................................185
   Mick Foy, Paul Barrow, and June M. Raine
13c Spontaneous Reporting: France ..................................................................203
   Jacques Caron, Sophie Gautier, and Michel Mallaret
13d How Pharmacovigilance is Organized in Germany ..........................................207
   Ulrich Hagemann and Norbert Paeschke
13e Organization of Pharmacovigilance in the Netherlands .................................213
   Eugène Van Puijenbroek and Kees Van Grootheest
13f Pharmacovigilance in Spain .........................................................................217
   Dolores Montero, Miguel Angel Maciá, and César De La Fuente
13g Italian Pharmacovigilance System ................................................................221
   Laura Sottosanti and Fernanda Ferrazin
13h Pharmacovigilance in Turkey ........................................................................225
   Sinem Ezgi Gülmez

Pharmacovigilance in the Americas
14a Spontaneous Reporting and Pharmacovigilance Practice: USA .........................229
   Min-Chu Chen, Solomon Iyasu, Alfred Sorbello, and Linda Scarazzini
14b Spontaneous Reporting in Mexico ..................................................................241
   Alejandra Rosete and Ricardo Benítez-Vázquez
14c Pharmacovigilance in Argentina: A Lot Done, A Lot To Do .............................245
   Luis Alesso and Raquel Herrera Comoglio

Pharmacovigilance in Asia
15a Pharmacovigilance and Risk Management in Japan ........................................249
   Kiyoshi Kubota and Tsugumichi Sato
15b Pharmacovigilance in Hong Kong .................................................................259
   Thomas Y.K. Chan
15c Pharmacovigilance in China ............................................................................263
   Hong-Hao Zhou, Fan-Dian Zeng, and Jie Tang
15d China ............................................................................................................267
   Kenneth Hartigan-Go and Althea Bongat
15e Malaysia .........................................................................................................271
   Kenneth Hartigan-Go and Althea Bongat
15f Philippines ......................................................................................................273
   Kenneth Hartigan-Go and Althea Bongat
15g Singapore .......................................................................................................277
   Kenneth Hartigan-Go and Althea Bongat
CONTENTS

15h Thailand ................................................................. 279
   Kenneth Hartigan-Go and Althea Bongat

15i Vietnam ................................................................. 283
   Kenneth Hartigan-Go and Althea Bongat

15j Pharmacovigilance in India ..................................... 285
   Pipasha Biswas

Pharmacovigilance in New Zealand and Australia

16a Pharmacovigilance in New Zealand .......................... 291
   Mira Harrison-Woolrych, Michael Tatley, and Desiree Kunac

16b Pharmacovigilance: Australia ................................. 295
   John MCEwen

Pharmacovigilance in Africa

17 Pharmacovigilance in Africa .................................... 299
   Alexander N.O. Dodoo and Haggar H. Ampadu

III SIGNAL DETECTION/GENERATION IN SPONTANEOUS REPORTING
PROGRAMS AND OTHER SOURCES: FROM SPONTANEOUS REPORTING TO
PHARMACOEPIDEMIOLOGY

18 Vaccine Safety Surveillance ....................................... 305
   Emily Jane Woo, Jerry Labadie, and M. Miles Braun

19 How We Assess Causality ......................................... 319
   Judith K. Jones and Elyse Kingery

20 Quantitative Signal Detection and Analysis in Pharmacovigilance . 331
   Andrew Bate, Antoine Pariente, Manfred Hauben, and Bernard Bégaud

21 Self-Controlled Case Series Analysis .......................... 355
   Paddy Farrington

22 Prescription–Event Monitoring (PEM): The Evolution to the New Modified PEM and its
   Support of Risk Management .................................... 359
   Deborah Layton and Saad Shakir

23 Prescription–Event Monitoring in New Zealand ................ 385
   Mira Harrison-Woolrych

24 A Description of the European Network of Centres for Pharmacoepidemiology and
   Pharmacovigilance as a Global Resource for Pharmacovigilance and
   Pharmacoepidemiology .............................................. 403
   Thomas Goedecke and Peter Arlett

25 Overview of North American Databases ........................ 409
   Brian L. Strom, Rita Schinnar, and Judith L. Kinman

26 The Clinical Practice Research Datalink: The New 54 Million Fully Integrated Research
   Data and Clinical Trial System .................................. 421
   John Parkinson

27 Active Surveillance: The United States Food and Drug Administration’s
   Sentinel Initiative ..................................................... 429
   Ryan M. Carnahan, Carlos J. Bell, and Richard Platt
CONTENTS

28 Leveraging Routinely Collected Healthcare Data to Scale Up Drug Safety Surveillance: The EU-ADR Experience
Gianluca Trifirò and Preciosa Coloma

29 Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership
Paul Stang, Patrick Ryan, Abraham G. Hartzema, David Madigan, J. Marc Overhage, Emily Welebob, Christian G. Reich, and Thomas Scarnecchia

IV PHARMACOVIGILANCE AND DRUG/SYSTEM ORGAN CLASSES

30 Mechanisms of Adverse Drug Reactions
Munir Pirmohamed

31 Fatal Medication Errors and Adverse Drug Reactions
Robin E. Ferner and Sarah E. McDowell

32 Dermatological Adverse Drug Reactions
Laurence Valeyrie-Allanore and Jean-Claude Roujeau

33 Gastrointestinal Adverse Drug Reactions
Angel Lanas Arbeloa and Carlos Sostres Homedes

34 Hematological Adverse Drug Reactions
Peter J. Carey

35 Hepatic Adverse Drug Reactions
Guruprasad P. Aithal and Dominique Larrey

36 Ocular Side Effects of Prescription Medications
Frederick W. Fraunfelder

37 Renal Adverse Drug Reactions
Gert A. Verpoorten

38 The Cardiovascular Spectrum of Adverse Drug Reactions
Charles Schubert and Judith Hsia

39 Neurological Adverse Events
Bradford B. Walters

Special Populations
40 Drug Safety in Pregnancy
Christina D. Chambers and Elizabeth B. Andrews

41 Pharmacovigilance in Pediatrics
M. Dianne Murphy, Judith Cope, and Solomon Iyasu

42 Drugs and the Elderly
Jamie J. Coleman

Special Product Classes
43 Anesthetic Adverse Drug Reactions
Anita Holdcroft and Karine Nouette-Gaulain

44 Pharmacoepidemiology as Part of Pharmacovigilance for Biologic Therapies
John Acquavella, Brian Bradbury, Cathy Critchlow, Jason B. Litten, J. Michael Sprafka, and John Sullivan

45 Surveillance for Medical Devices: USA
Thomas P. Gross
V CURRENT TOPICS

46 The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Children and Adolescents. ................................................................. 719
   J. Magno Zito, D.J. Safer, and Satish Valluri

47 Nonsteroidal Anti-inflammatory Drugs – Cyclooxygenase-2 Inhibitors: Risks and Benefits ........ 735
   K. Arnold Chan

48 Introduction to Pharmionics: The Vagaries in Ambulatory Patients’ Adherence to Prescribed Drug Dosing Regimens, and Some of Their Clinical and Economic Consequences .......... 751
   John Urquhart and Bernard Vrijens

49 Design and Implementation of Surveys to Assess Patient and Healthcare Provider Understanding of Risks and Safe Use Conditions ........................................... 769
   Kelly Hollis and Alicia Gilsenan

VI TRAINING AND EDUCATION AND DIRECTIONS

50 Eu2P: The First European Online Public–Private Joint Training Program in Pharmacovigilance and Pharmacoepidemiology ......................................................... 787
   Karine Palin, Christa Bataille, Stéphane Liège, Ralph Schimmer, and Annie Fourrier-Réglat

51 Teaching and Learning Pharmacovigilance ................................................................. 793
   Frank May

52 Practical Experience in Teaching Pharmacovigilance ................................................... 805
   Stephen Evans and Ian Douglas

53 An Historical Perspective of the Future of Pharmacovigilance ........................................ 807
   Nicholas Moore

Index ................................................................. 819
Contributors

ELIZABETH B. ANDREWS, PhD, MPH, FISPE
RTI Health Solutions, Research Triangle Institute, Research Triangle Park, NC, USA; School of Public Health and School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA

JOHN ACQUAVELLA, PhD
Executive Director, Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA

GURUPRASAD P. AITHAL, MBBS, MD, FRCP, PhD
Co-Director, National Institute for Health Research: Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK; University of Nottingham, Queen’s Medical Centre, Nottingham, UK

LUIS ALESSO, MD
Specialist in Pharmaceutical Medicine Professor in School of Medicine, National University of Córdoba, Argentina; Head of Pharmacovigilance Department, School of Public Health, National University of Córdoba, Argentina.

HAGGAR H. AMPADU, BSc, MS
Director of Operations, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, University of Ghana Medical School, Accra, Ghana

PETER ARLETT, BSc(Hons), MBBS, MRCP, FFPM
Head of Pharmacovigilance Department, Inspections & Human Medicines Pharmacovigilance Division, European Medicines Agency, London, UK

JEFFREY K. ARONSON, MA DPhil FRCP FBPharmacolS FFPM(Hon)
President Emeritus, British Pharmacological Society; Reader in Clinical Pharmacology, Nuffield Department of Primary Care Health Sciences, University of Oxford; Consultant Physician, Oxford University Hospitals NHS Trust, Oxford, UK

PRIYA BAHRI, PhD
Pharmacovigilance Lead for Guidelines and Risk Communication, European Medicines Agency, London, UK

PAUL BARROW, MD MSc FRCP, PhD
CHRISTA BATAILLE, LL.M.
Eu2P Legal Manager, Eu2P Central Office, Université de Bordeaux, Bordeaux, France

ANDREW BATE, PhD
Senior Director, Worldwide Safety & Regulatory Epidemiology, Pfizer Ltd, UK; Department of Computing and Mathematics, Brunel University, London, UK; New York University School of Medicine, New York, NY, USA

BERNARD BÉGAUD, MD, PhD
Department of Pharmacology, Université Bordeaux Segalen, Bordeaux, France

CARLOS J. BELL, MPH
Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Commander, US Public Health Service, Silver Spring, MD, USA

RICARDO BENÍTEZ-VÁZQUEZ, MD, CCRP
Clinical Trials Manager, Center of Pharmacological and Biotechnology Research. CIFBIOTEC, Mexico City, Mexico

JESSE A. BERLIN, ScD
Vice President and Head of Global Epidemiology, Johnson & Johnson, New Brunswick, NJ, USA

PIPASHA BISWAS, MD MFPM DM MRQA
Principal Consultant, Director & QPPV, Symogen Limited, London, UK

STELLA C.F. BLACKBURN, MB MS MA MSc FRCP(Ed) FISPE FFPM Dip Pharm Med LSHTM

ALTHEA BONGAT, RPh
Pharmacist and Masters Candidate in Pharmacology, University of the Philippines, Manila, Philippines

BRIAN BRADBURY, DSc
Director, Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA

M. MILES BRAUN, MD MPH
Consultant, North Potomac, MD, USA

ELLIOIT BROWN, MB, ChB, BMedSci, MRCGP, MFPM, FRCP(E)
Managing Director, Elliot Brown Consulting Ltd, Leeds, UK

PETER J. CAREY, FRCP, FRCPEd, FRCPath
Consultant Haematologist, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

RYAN M. CARNAHAN, PharmD, MS
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA

JACQUES CARON, MD
Professor of Pharmacology, Centre Regional de pharmacovigilance, University Hospital, Lille, France

CHRISTINA D. CHAMBERS, PhD, MPH
Professor, Co-Director, Center for Promotion of Maternal Health and Infant Development, Department of Pediatrics and Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA

K. ARNOLD CHAN, MD, ScD, FISPE
National Taiwan University Hospital, Taipei, Taiwan
THOMAS Y.K. CHAN, MBChB, MD, PhD, FRCP, FHKCP, FHKAM (Medicine)
Professor and Director, Centre for Food and Drug Safety, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

MIN-CHU CHEN, MS, RPh
Acting Director, Deputy Director, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

JAMIE J COLEMAN, MD, MA, MRCP(UK)
Senior Clinical Lecturer in Clinical Pharmacology & Medical Education, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham; Honorary Consultant Physician, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

PRECIOSA COLOMA, MD, PhD
Assistant Professor, Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands

RAQUEL HERRERA COMOGLIO, MD, MSc, PharmD
Head of Pharmacovigilance Service, Hospital Nacional de Clínicas, School of Medicine, National University of Córdoba, Argentina

JUDITH COPE, MD, MPH
Director of Safety, Office Pediatric therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA

CATHY CRITCHLOW, PhD
Executive Director & Head, Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA

BRENDA CROWE, PhD
Research Advisor, Global Statistical Sciences, Eli Lilly and Company, Indianapolis, IN, USA

CÉSAR DE LA FUENTE, BPharm
Head of Unit, Pharmacoepidemiology, Division of Pharmacoepidemiology and Pharmacovigilance, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain

IAN DOUGLAS, BSc MSc PhD
Lecturer, London School of Hygiene and Tropical Medicine, London, UK

ALEXANDER N.O. DODOO, BPharm, MSc, PhD, FPSGH, FPCPharm, MRPharmS
Associate Professor and Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, University of Ghana Medical School, Accra, Ghana

BRIAN EDWARDS, BSc MD MRCP
Principal Consultant, NDA Regulatory Science Ltd, Leatherhead, UK

STEPHEN EVANS, BA, MSc, FFRCP(Edin), Hon FRCP
Professor of Pharmacoepidemiology, London School of Hygiene and Tropical Medicine, London, UK

TOMMY ERIKSSON, PhD
Professor, Lund University, Faculty of Medicine, Institution for Laborative Medicine, Lund, Sweden

PADDY FARRINGTON, PhD
Professor of Statistics, Department of Mathematics and Statistics, Faculty of Mathematics, Computing and Technology, The Open University, Milton Keynes, UK